Teva Pharmaceutical Industries (TEVJF) Capital Expenditures (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Capital Expenditures across 10 years of filings, most recently posting $168.0 million for Q1 2026.

• Quarterly Capital Expenditures rose 32.28% year-over-year to $168.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $542.0 million (up 8.18% YoY) and the FY2025 annual result came in at $501.0 million, up 0.6% from the prior year.
• Capital Expenditures improved to $168.0 million in Q1 2026, from $142.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $168.0 million in Q1 2026 and troughed at $96.0 million in Q2 2025.
• A 5-year average of $131.8 million and a median of $129.0 million in 2024 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2024 — Capital Expenditures fell 18.49% — and 2026, when it soared 32.28%.
• Tracing TEVJF's Capital Expenditures over 5 years: stood at $142.0 million in 2022, then decreased by 16.2% to $119.0 million in 2023, then rose by 8.4% to $129.0 million in 2024, then increased by 10.08% to $142.0 million in 2025, then grew by 18.31% to $168.0 million in 2026.
• Business Quant data shows TEVJF's Capital Expenditures at $168.0 million in Q1 2026, $142.0 million in Q4 2025, and $136.0 million in Q3 2025.